Pharmacist Diabetes | New Drugs | Weight Management Podcast 1 credit hour

GLP-1 receptor agonists continue to generate clinical and media buzz, with new formulations, new approvals, and expanding areas of research. This course explores key updates, including the FDA approval of the first oral GLP-1 for chronic weight management and ongoing investigations into GLP-1 therapies for conditions beyond diabetes and obesity. You will gain a timely overview of recent developments in GLP-1s and how pharmacists can anticipate and support their evolving role in patient care.

Available in Subscription

This course is included in the following subscription:

Pharmacist CE Subscription

Pharmacist CE Subscription

Renewed Annually
$99.00 / year

Learning Objectives

Upon successful completion of this course, pharmacists should be able to:
1. Summarize recent regulatory and clinical updates related to GLP-1 receptor agonists, including new formulations.
2. Describe emerging areas of research into the use of GLP-1 therapies beyond diabetes and obesity treatment.

Faculty

Rachel Maynard, PharmD

GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls

Disclosures:

Rachel Maynard has no relevant financial relationships with ineligible companies to disclose.

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BCADM, CDCES, FCCP

Professor, Pharmacy Practice and Director, PGY2 Ambulatory Care
Residency Program
Midwestern University College of Pharmacy 

Disclosures:

Christie Schumacher is a speaker for and is on the advisory board for Abbott. All relevant financial relationships have been mitigated.

Course Details